Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE.
To review the results of the first anti-IgE agent to undergo clinical evaluation in the treatment of allergic asthma and allergic rhinitis. Treatment protocols conducted in Europe and the United States in moderate to severe allergic asthmatic patients who continued to show symptoms despite treatment with inhaled corticosteroids with the addition of monoclonal humanized anti-IgE treatment. Double-blind, placebo-controlled studies, published and in press, are reviewed. Treatment with anti-IgE allowed a decrease in inhaled corticosteroid and rescue medication use and significantly reduced the incidence and frequency of asthma exacerbations among these patients over a 28-week time period and a 6-month extension period. Anti-IgE shows great promise as an adjunctive therapy in moderate to severe asthmatic patients.